<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: We explored the putative anti-inflammatory effects of <z:chebi fb="0" ids="17154">nicotinamide</z:chebi> against experimental <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>DESIGN: Prospective laboratory study </plain></SENT>
<SENT sid="2" pm="."><plain>SETTING: Research laboratory in a university teaching hospital </plain></SENT>
<SENT sid="3" pm="."><plain>SUBJECTS: Adult male Sprague-Dawley rats (250-300 g) </plain></SENT>
<SENT sid="4" pm="."><plain>INTERVENTIONS: The <z:chebi fb="11" ids="22586">antioxidant</z:chebi>, radical scavenging, and anti-inflammatory actions of <z:chebi fb="0" ids="17154">nicotinamide</z:chebi> were evaluated using a panel of acellular assays and <z:chebi fb="0" ids="16412">lipopolysaccharide</z:chebi>-stimulated RAW 264.7 and BV2 cells </plain></SENT>
<SENT sid="5" pm="."><plain>Animals were subjected to transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> for 90 mins </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="17154">Nicotinamide</z:chebi> (500 mg/kg) or vehicle was given intravenously at reperfusion <z:hpo ids='HP_0003674'>onset</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>MEASUREMENTS AND MAIN RESULTS: <z:chebi fb="0" ids="17154">Nicotinamide</z:chebi> effectively inhibited nuclear factor-κB translocation and binding activity as well as the production of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor-α, <z:chebi fb="95" ids="16301">nitrite</z:chebi>/nitrate, and interleukin-6 in the <z:chebi fb="0" ids="16412">lipopolysaccharide</z:chebi>-stimulated RAW 264.7 and BV2 cells (p &lt; .05, respectively) but exhibited weak <z:chebi fb="11" ids="22586">antioxidant</z:chebi> and radical-scavenging actions </plain></SENT>
<SENT sid="8" pm="."><plain>Relative to controls, <z:chebi fb="0" ids="17154">nicotinamide</z:chebi>-treated animals had significant reductions in neutrophil and macrophage/activated microglial infiltration in the ischemic brain by 53% and 77% (p &lt; .05, respectively) </plain></SENT>
<SENT sid="9" pm="."><plain>Additionally, <z:chebi fb="0" ids="17154">nicotinamide</z:chebi> significantly attenuated phosphorylation of nuclear factor-κB's inhibitory protein, nuclear factor-κB translocation and binding activity, and the synthesis of inducible nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> in the ischemic brain (p &lt; .05, respectively) </plain></SENT>
<SENT sid="10" pm="."><plain>Consequently, <z:chebi fb="0" ids="17154">nicotinamide</z:chebi> effectively reduced <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> and improved neurobehavioral outcome by 43% and 50% (p &lt; .05, respectively) </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: <z:chebi fb="0" ids="17154">Nicotinamide</z:chebi> effectively attenuated postischemic nuclear factor-kappa]B activation and exhibited robust anti-inflammatory actions against <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> </plain></SENT>
</text></document>